These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 15895440)

  • 1. Gastric GI stromal tumors (GISTs): the role of surgery in the era of targeted therapy.
    Heinrich MC; Corless CL
    J Surg Oncol; 2005 Jun; 90(3):195-207; discussion 207. PubMed ID: 15895440
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gastrointestinal stromal tumors and the evolution of targeted therapy.
    Sanborn RE; Blanke CD
    Clin Adv Hematol Oncol; 2005 Aug; 3(8):647-57. PubMed ID: 16167051
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rhabdomyosarcomatous differentiation in gastrointestinal stromal tumors after tyrosine kinase inhibitor therapy: a novel form of tumor progression.
    Liegl B; Hornick JL; Antonescu CR; Corless CL; Fletcher CD
    Am J Surg Pathol; 2009 Feb; 33(2):218-26. PubMed ID: 18830121
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gastrointestinal stromal tumors (GISTs): a pathology view point.
    Sornmayura P
    J Med Assoc Thai; 2009 Jan; 92(1):124-35. PubMed ID: 19260254
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gastrointestinal stromal tumor.
    Gupta P; Tewari M; Shukla HS
    Surg Oncol; 2008 Aug; 17(2):129-38. PubMed ID: 18234489
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Small-molecule inhibitors against KIT and PDGFRs especially in GISTs].
    Shiba K; Matsumoto T; Hirota S
    Gan To Kagaku Ryoho; 2009 Jul; 36(7):1080-5. PubMed ID: 19620796
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate.
    Wardelmann E; Merkelbach-Bruse S; Pauls K; Thomas N; Schildhaus HU; Heinicke T; Speidel N; Pietsch T; Buettner R; Pink D; Reichardt P; Hohenberger P
    Clin Cancer Res; 2006 Mar; 12(6):1743-9. PubMed ID: 16551858
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Activating mutations in receptor tyrosine kinases with relevance for treatment of gastrointestinal stromal tumors].
    Wardelmann E; Merkelbach-Bruse S; Büttner R; Schildhaus HU
    Verh Dtsch Ges Pathol; 2007; 91():165-8. PubMed ID: 18314611
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Therapeutic targets in gastrointestinal stromal tumors].
    Wardelmann E; Schildhaus HU; Merkelbach-Bruse S; Büttner R
    Verh Dtsch Ges Pathol; 2006; 90():73-9. PubMed ID: 17867582
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathologic and molecular heterogeneity in imatinib-stable or imatinib-responsive gastrointestinal stromal tumors.
    Agaram NP; Besmer P; Wong GC; Guo T; Socci ND; Maki RG; DeSantis D; Brennan MF; Singer S; DeMatteo RP; Antonescu CR
    Clin Cancer Res; 2007 Jan; 13(1):170-81. PubMed ID: 17200352
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Decrease of CD117 expression as possible prognostic marker for recurrence in the resected specimen after imatinib treatment in patients with initially unresectable gastrointestinal stromal tumors: a clinicopathological analysis.
    Mearadji A; den Bakker MA; van Geel AN; Eggermont AM; Sleijfer S; Verweij J; de Wilt JH; Verhoef C
    Anticancer Drugs; 2008 Jul; 19(6):607-12. PubMed ID: 18525320
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gastrointestinal stromal tumor: 5 years later.
    van der Zwan SM; DeMatteo RP
    Cancer; 2005 Nov; 104(9):1781-8. PubMed ID: 16136600
    [TBL] [Abstract][Full Text] [Related]  

  • 13. c-Kit/PDGFRA gene status alterations possibly related to primary imatinib resistance in gastrointestinal stromal tumors.
    Miselli FC; Casieri P; Negri T; Orsenigo M; Lagonigro MS; Gronchi A; Fiore M; Casali PG; Bertulli R; Carbone A; Pierotti MA; Tamborini E; Pilotti S
    Clin Cancer Res; 2007 Apr; 13(8):2369-77. PubMed ID: 17438095
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gastrointestinal stromal tumours.
    Connolly EM; Gaffney E; Reynolds JV
    Br J Surg; 2003 Oct; 90(10):1178-86. PubMed ID: 14515284
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Kinase mutations and imatinib mesylate response for 64 Taiwanese with advanced GIST: preliminary experience from Chang Gung Memorial Hospital.
    Yeh CN; Chen TW; Lee HL; Liu YY; Chao TC; Hwang TL; Jan YY; Chen MF
    Ann Surg Oncol; 2007 Mar; 14(3):1123-8. PubMed ID: 17195905
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathology of gastrointestinal stromal tumors.
    Hirota S; Isozaki K
    Pathol Int; 2006 Jan; 56(1):1-9. PubMed ID: 16398673
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gastrointestinal stromal tumors presenting as omental masses--a clinicopathologic analysis of 95 cases.
    Miettinen M; Sobin LH; Lasota J
    Am J Surg Pathol; 2009 Sep; 33(9):1267-75. PubMed ID: 19440146
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Different factors are responsible for predicting relapses after primary tumors resection and for imatinib treatment outcomes in gastrointestinal stromal tumors.
    Rutkowski P; Debiec-Rychter M; Nowecki ZI; Wozniak A; Michej W; Limon J; Siedlecki JA; Jerzak Vel Dobosz A; Grzesiakowska U; Nasierowska-Guttmejer A; Sygut J; Nyckowski P; Krawczyk M; Ruka W
    Med Sci Monit; 2007 Nov; 13(11):CR515-522. PubMed ID: 17968300
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Gastrointestinal stromal tumors: a broad clinical spectrum from incidental -discovery to acute gastrointestinal bleeding].
    Siewert E; Tietze L; Maintz C; Geier A; Dietrich CG; Matern S; Gartung C
    Z Gastroenterol; 2004 Mar; 42(3):233-42. PubMed ID: 15022111
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours.
    Lasota J; Miettinen M
    Histopathology; 2008 Sep; 53(3):245-66. PubMed ID: 18312355
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.